Intracavitary Chemotherapy of Polycystic Craniopharyngioma with Bleomycin

1999 ◽  
Vol 141 (5) ◽  
pp. 547-549 ◽  
Author(s):  
A. Savas ◽  
E. Arasıl ◽  
F. Batay ◽  
M. Selcuki ◽  
Y. Kanpolat
Keyword(s):  
Intracavitary Chemotherapy

Hyperthermia and Intracavitary Chemotherapy in Prevention and Treatment of Malignant Effusions

2012 ◽  
pp. 123-150 ◽  
Author(s):  
Gianfranco Baronzio ◽  
Giammaria Fiorentini ◽  
Marco Ballerini ◽  
Valter Cassuti ◽  
Giorgio Forzenigo ◽  
...  
Keyword(s):  
Prevention And Treatment ◽  
Intracavitary Chemotherapy ◽  
Malignant Effusions

Sustained-Release Methotrexate For Intracavitary Chemotherapy

1994 ◽  
Vol 83 (3) ◽  
pp. 429-432 ◽  
Author(s):  
Etienne Chatelut ◽  
Peter Suh ◽  
Sinil Kim
Keyword(s):  
Sustained Release ◽  
Intracavitary Chemotherapy

Surgery Followed by Intracavitary plus Systemic Chemotherapy in Malignant Pleural Mesothelioma

1996 ◽  
Vol 82 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Marco Colleoni ◽  
Francesco Sartori ◽  
Francesco Calabrò ◽  
Patrizia Nelli ◽  
Giovanni Vicario ◽  
...  
Keyword(s):  
Median Survival ◽  
Systemic Chemotherapy ◽  
Renal Toxicity ◽  
Residual Disease ◽  
Intrapleural Chemotherapy ◽  
Intracavitary Chemotherapy ◽  
Minimal Disease ◽  
Single Modality ◽  
Minimal Residual ◽  
Treatment Surgery

Aims and background Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) for 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.

Metastatic Ovarian Adenocarcinoma in a Dog Treated with Ovariohysterectomy and Intracavitary Chemotherapy

2007 ◽  
Vol 38 (3/4) ◽  
pp. 63-68
Author(s):  
Teruo ITOH ◽  
Kazuyuki UCHIDA ◽  
Atsuko KOJIMOTO ◽  
Ayako IKEDA ◽  
Kazumi NIBE ◽  
...  
Keyword(s):  
Ovarian Adenocarcinoma ◽  
Intracavitary Chemotherapy

Intracavitary chemotherapy

1985 ◽  
Vol 3 (3) ◽  
pp. 205-233 ◽  
Author(s):  
Maurie Markman ◽  
Franco M. Muggia
Keyword(s):  
Intracavitary Chemotherapy

Intracavitary chemotherapy (Gliadel®) for recurrent esthesioneuroblastoma: case report and review of the literature

2005 ◽  
Vol 77 (1) ◽  
pp. 47-51 ◽  
Author(s):  
Michael C. Park ◽  
Charles E. Weaver Jr ◽  
John E. Donahue ◽  
Prakash Sampath
Keyword(s):  
Case Report ◽  
Review Of The Literature ◽  
Intracavitary Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document